Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyFrancesco Passamonti, Celestino Ferrandina, Carlo Gambacorti‐Passerini et al.|The Lancet Haematology|2020Cited by 553
Genetic and phenotypic attributes of splenic marginal zone lymphomaFerdinando Bonfiglio, Estella Matutes, Alessio Bruscaggin et al.|Blood|2021Cited by 96
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphomaEnrico Derenzini, Anas Younes|Blood Cancer Journal|2011Cited by 70
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphomaEnrico Derenzini, Pier Luigi Zinzani|Oncotarget|2015Cited by 58
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S. Davids, Ian W. Flinn, Owen A. O’Connor et al.|Blood Advances|2021Cited by 21